Kymera Therapeutics, Inc. - Common Stock (KYMR)

Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET.

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET.

WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) Phase 2 trials to more rapidly progress towards pivotal studies.

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:KYMRNASDAQKYMR)(NASDAQ:GILDNASDAQGILD,(OTCQX:RHHBY),(NASDAQ:AMGNNASDAQ) EQNX::TICKER_END

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer market is projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033. The report said: “Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period. The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Kymera Therapeutics, Inc. NASDAQ: KYMRNASDAQKYMR)(NASDAQ: GILDNASDAQGILD, Amgen (NASDAQ: AMGNNASDAQ).

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 financial results on May 2, 2024, and will host a conference call at 8:30 a.m. ET.

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera sold and issued 3,884,158 shares of its common stock, which includes 1,633,663 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of its common stock in the offering. The shares of common stock were sold at a public offering price of $25.25 per share and the pre-funded warrants were sold at a public offering price of $25.2499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering were approximately $316.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,250,495 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,640,594 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $25.25 per share and the pre-funded warrants are being sold at a public offering price of $25.2499 per pre-funded warrants, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Kymera from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ option to purchase additional shares. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional $41.25 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on January 9, 2024, subject to the satisfaction of customary conditions.

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQKYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.